Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 52-Week Low After Earnings Miss

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) reached a new 52-week low on Wednesday following a weaker than expected earnings announcement. The company traded as low as $5.33 and last traded at $5.36, with a volume of 3506472 shares. The stock had previously closed at $5.58.

The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.10). The company had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.46% and a negative net margin of 2.02%.

Analysts Set New Price Targets

Separately, Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the company. According to MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of “Hold”.

Bayer Aktiengesellschaft Price Performance

The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $21.06 billion, a price-to-earnings ratio of -20.62 and a beta of 1.10. The stock has a 50-day moving average price of $7.44 and a 200 day moving average price of $7.43.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.